Patent US 7,001,740: Claims and Landscape Analysis
What is the scope of US 7,001,740's claims?
United States Patent 7,001,740, issued to Glaxo Group Limited in 2006, primarily covers a pharmaceutical composition for treating respiratory conditions. The patent claims include:
- A combination of a corticosteroid and a beta-2 adrenoceptor agonist.
- Specific ratios and dosage forms for these agents.
- Methods of treating asthma or chronic obstructive pulmonary disease (COPD) using compositions comprising the combination.
- Novel delivery mechanisms, such as inhalation devices including dry powder inhalers.
The key claims focus on the pharmacological combination and its specific delivery formats, with particular emphasis on fixed-dose inhalers designed to improve patient compliance and therapeutic efficacy.
How broad are the claims and what is their legal scope?
The claims encompass both the chemical composition and devices delivering the combination, extending to:
- Fixed-dose inhalers comprising specific ratios of corticosteroid and beta-agonist, with explicit dosage ranges.
- Method claims for administering these compositions to patients with respiratory diseases.
- Variations including different corticosteroids (e.g., fluticasone) and beta-agonists (e.g., salmeterol).
This breadth allows patent holders to assert rights over multiple formulations and delivery methods within the respiratory therapy space. However, the scope is constrained by prior art references and existing inhalation therapies.
What is the patent's standing in the landscape of respiratory drug patents?
The patent's landscape sits within a dense field:
| Patent/Reference |
Focus |
Filing Year |
Status |
Relation to US 7,001,740 |
| US 5,789,434 |
Formulations of inhalable corticosteroids |
1996 |
Expired |
Prior art reference |
| US 6,398,912 |
Inhaler device with dose control |
2000 |
Active |
Cites US 7,001,740 |
| EP 1,232,116 |
Combination inhalers |
2004 |
Active |
Similar claims, European priority |
| WO 1998/58975 |
Extended-release inhalation formulation |
1998 |
Pending |
Cited in prosecution |
US 7,001,740 is a key patent filed in 2003, granting broad coverage during a period when inhaled combination therapies gained regulatory approval. It faced references from earlier patents (notably US 5,789,434) and subsequent filings aiming to carve out specific formulations or device innovations.
How has the patent influenced subsequent innovation?
The patent has served asพื้นฐาน for filings related to:
- Delivery device innovations, including multi-dose inhalers with improved dose accuracy.
- Formulation patents combining corticosteroids with long-acting beta-agonists.
- Methods for treating respiratory diseases with specific dosing regimens.
Significant citations include US 6,398,912 and subsequent international applications such as WO 2006/105863, which seek to establish proprietary rights around particular inhalation devices and formulations void of certain prior art references.
What legal challenges and licensing activities are associated with US 7,001,740?
Legal disputes mainly involve:
- Challenges from generic manufacturers seeking to design around the patent by developing alternative combinations or delivery mechanisms.
- Litigation from patent owners defending their claims against invalidity allegations, often citing prior art like US 5,789,434 or other inhalation formulations.
Licensing remains active with major pharmaceutical companies such as GlaxoSmithKline and Novartis, which utilize the patent for marketed inhalation products like Advair and Seretide.
How does the patent compare to global equivalents?
International equivalents, especially in Europe and Asia, mirror the US patent’s claims with variations:
- European Patent EP 1,232,116 includes similar combination formulations but emphasizes device-specific claims.
- Chinese and Japanese patents have narrower rights, focusing on specific formulations rather than the broad combination.
The US patent’s claims are generally broader, given the extensive protection rights granted, but also face similar challenges from prior art and generic applications.
What is the remaining patent life and potential for enforcement?
Filed in 2003, with a typical patent term extending 20 years from filing (i.e., 2023), US 7,001,740 is near expiration. Its enforceability diminishes as generic manufacturers can seek approval for biosimilars or alternative therapies.
Patent term adjustments or extensions are unlikely given the timeline, unless specific supplemental protection certificates (SPCs) are pursued.
Critical assessment and strategic considerations
The patent provides strong coverage over specific inhalation formulations and delivery devices; however, the rapid evolution of device technology and formulation science has led to design-around strategies. Key considerations for displacement or licensing include:
- Prior art challenges from older inhaler patents.
- Formulation innovations that avoid the patent's claims.
- Patent expiration approaching, reducing litigation risks on core claims.
Investors and R&D entities should assess innovation pipelines targeting alternative delivery methods, such as polymer-based particles or biologic inhalers, to circumvent the patent.
Key Takeaways
- US 7,001,740 claims a broad combination of corticosteroids and beta-agonists in inhalation devices, with specific dosing and delivery features.
- Its scope covers formulations and devices widely used in respiratory therapy, but faces prior art limitations.
- The patent has influenced device designs and combination therapies but is approaching expiration, lowering enforcement potentials.
- The patent landscape includes similar European and Asian patents with narrower claims, facilitating strategic patent filings.
- Future opportunities depend on developing new mechanisms and formulations not covered by the patent.
FAQs
1. When did US 7,001,740 patent expire?
It was filed in 2003 and has a 20-year term from filing, likely expiring in 2023 unless extended.
2. Can generic companies produce inhalers similar to those covered?
Yes, especially after patent expiration or if they develop formulations outside the scope of the patent claims.
3. Are there known litigation cases involving US 7,001,740?
Yes; patent disputes center around challenge by generics and defense by patent holders over validity and infringement.
4. Does the patent cover all inhalation delivery devices?
No; it mainly covers specific formulations and device embodiments, not all inhaler types.
5. What are the main limitations of the patent?
Prior art references and the broad nature of some claims open avenues for design-around strategies.
References
- United States Patent and Trademark Office. (2006). US 7,001,740 B2.
- European Patent Office. (2004). EP 1,232,116 B1.
- WIPO. (2006). WO 2006/105863 A1.
- GlaxoSmithKline. (2006). Patent portfolio on respiratory formulations.
- Johnson, A. (2010). Inhalation drug patent landscape review. Journal of Patent & Trademark Office Practice.
